These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8981334)

  • 21. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate.
    Frenkel Y; Kopernik G; Lazer S; Tugendreich D; Zmira N; Oettinger M; Tendler R; Serr DM
    Maturitas; 1994 Nov; 20(1):31-6. PubMed ID: 7877518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms.
    Van Leusden HA; Albertyn G; Verlaine C; Van Ruymbeke J
    Int J Fertil Menopausal Stud; 1993; 38(4):210-8. PubMed ID: 8401679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
    Raynaud JP; Lévrier M; Calaf J; Laur C; Pélissier C
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):309-18. PubMed ID: 15860275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of a low-dose of Oesclim (25 mcg daily) in the management of symptomatic menopausal women: a French open-label study.
    Elia D; Tamborini A; Leocmach Y; Chadha-Boreham H
    Curr Med Res Opin; 2000; 16(2):94-106. PubMed ID: 10893653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
    Rohr UD; Nauert C; Stehle B
    Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen replacement therapy and the estraderm transdermal system.
    Youngkin EQ
    Nurse Pract; 1990 May; 15(5):19-26, 31. PubMed ID: 2342664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome.
    Smith RN; Studd JW; Zamblera D; Holland EF
    Br J Obstet Gynaecol; 1995 Jun; 102(6):475-84. PubMed ID: 7632640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages.
    Evans SF; Davie MW
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):79-84. PubMed ID: 8706298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with Systen, a new transdermal form of hormone replacement therapy.
    Corson SL
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():36-44. PubMed ID: 8499958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of Menorest in two positive-controlled studies.
    Pornel B
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S35-7. PubMed ID: 8732472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal hormonal replacement therapy with transdermal progestin every second month.
    Lindgren R; Risberg B; Hammar M; Berg G
    Maturitas; 1995 Jun; 22(1):25-30. PubMed ID: 7666813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
    Sajtos B; Herold J; Winkler UH; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of microbial proliferation and phototoxic potential of a new matrix patch for estradiol delivery.
    Mulberry GK; Della-Cioppa G; Monza G; Harper RA; Oelrich DM
    Maturitas; 1996 Nov; 25(3):223-9. PubMed ID: 8981340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Menorest: a clinical overview.
    Wren B
    Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S27-9. PubMed ID: 8666124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of transdermal oestradiol (Estraderm TTS) in hypertensive postmenopausal women.
    Foidart JM
    Br J Clin Pract Suppl; 1996 Sep; 86():14-6. PubMed ID: 8995005
    [No Abstract]   [Full Text] [Related]  

  • 37. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
    Reginster JY; Donazzolo Y; Brion N; Lins R
    Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative study of the acceptability of a new estradiol Tx 11323 (A) gel and a transdermal matrix system].
    Gelas B; Thébault J; Roux I; Herbrecht F; Zartarian M
    Contracept Fertil Sex; 1997 Jun; 25(6):470-4. PubMed ID: 9280552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
    Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
    Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test.
    Smits MG; van der Meer YG; Pfeil JP; Rijnierse JJ; Vos AJ
    Headache; 1994 Feb; 34(2):103-6. PubMed ID: 8163364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.